OtherBASIC SCIENCE INVESTIGATIONS
Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
Sara Ahlgren, Anna Orlova, Helena Wållberg, Monika Hansson, Mattias Sandström, Richard Lewsley, Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev and Joachim Feldwisch
Journal of Nuclear Medicine July 2010, 51 (7) 1131-1138; DOI: https://doi.org/10.2967/jnumed.109.073346
Sara Ahlgren
Anna Orlova
Helena Wållberg
Monika Hansson
Mattias Sandström
Richard Lewsley
Anders Wennborg
Lars Abrahmsén
Vladimir Tolmachev
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 51, Issue 7
July 2010
Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
Sara Ahlgren, Anna Orlova, Helena Wållberg, Monika Hansson, Mattias Sandström, Richard Lewsley, Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev, Joachim Feldwisch
Journal of Nuclear Medicine Jul 2010, 51 (7) 1131-1138; DOI: 10.2967/jnumed.109.073346
Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
Sara Ahlgren, Anna Orlova, Helena Wållberg, Monika Hansson, Mattias Sandström, Richard Lewsley, Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev, Joachim Feldwisch
Journal of Nuclear Medicine Jul 2010, 51 (7) 1131-1138; DOI: 10.2967/jnumed.109.073346
Jump to section
Related Articles
Cited By...
- Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
- ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
- PET of EGFR Expression with an 18F-Labeled Affibody Molecule
- Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties